INO Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Participate in December Investor Conferences

10 days ago - By: Zacks Investment Research

Inovio (INO) Upgraded to Buy: Here's Why

13 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Announces Pricing of $25 Million Public Offering

14 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Announces Proposed Public Offering

14 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

21 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

24 days ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Reports Inducement Grant Under Inducement Plan

2 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Reports Inducement Grant Under Inducement Plan

4 months ago - By: Benzinga

Earnings Outlook For Inovio Pharmaceuticals

15 days ago - By: Benzinga - Mentions: OGN TACT IMDX QRHC ...

Earnings Scheduled For November 10, 2025

a month ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

a month ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

a month ago - By: Inovio Pharmaceuticals, Inc.

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

2 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Participate in Upcoming Scientific Conferences

3 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA PGEN

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

3 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

3 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: The Motley Fool

Inovio Cuts Q2 Losses by 27%

3 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Zacks Investment Research - Mentions: AGEN

Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: GILD DERM ZVRA

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

4 months ago - By: Inovio Pharmaceuticals, Inc.

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

4 months ago - By: Zacks Investment Research - Mentions: DNTH

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

4 months ago - By: Zacks Investment Research - Mentions: VTGN

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

4 months ago - By: Inovio Pharmaceuticals, Inc.

INOVIO PHARMACEUTICALS INC (INO) Stock News

INO Latest News, Press Relases and Analysis

INOVIO to Participate in December Investor Conferences

Inovio (INO) Upgraded to Buy: Here's Why

INOVIO Announces Pricing of $25 Million Public Offering

INOVIO Announces Proposed Public Offering

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO Reports Inducement Grant Under Inducement Plan

Earnings Outlook For Inovio Pharmaceuticals

Earnings Scheduled For November 10, 2025

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

INOVIO to Participate in Upcoming Scientific Conferences

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Inovio Cuts Q2 Losses by 27%

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025